Definiums LSD formula produces 'best data ever seen' in pivotal depression trial
Definium has announced positive results from a Phase 3 trial testing its LSD-based formula for depression, with the CEO calling it the best data ever seen in a pivotal depression trial. The therapy met its primary endpoint, showing significant reduction in depressive symptoms compared to placebo.
Background
- Definium (formerly MindMed) is a Canadian biotech company focused on developing psychedelic-based therapies, particularly LSD, for psychiatric conditions. It is one of the more prominent publicly traded companies in the "psychedelic medicine" space.
- LSD (lysergic acid diethylamide) is a classic hallucinogen that was studied for psychiatric use in the 1950s-60s before being banned. In recent years, researchers have revived interest in low-dose psychedelics for treating depression, anxiety, and addiction.
- This is a Phase 2b (mid-stage) clinical trial, not yet FDA-approved. "Pivotal" usually refers to late-stage trials that could support approval, so the CEO's phrasing suggests they view this as a definitive result.
- "Best data ever seen" is unusually strong promotional language for a clinical trial result; many experts will wait for peer-reviewed publication and regulatory review.
- The trial tested a proprietary formulation of LSD (likely a controlled-dose, shorter-duration version) against placebo in patients with major depressive disorder. Positive results could set up a race with other psychedelic drug developers like Compass Pathways (psilocybin) and Lykos (MDMA).